Bioxytran (BIXT) News Today $0.09 0.00 (-3.11%) As of 09/15/2025 03:58 PM Eastern Add Compare Share Share Headlines Stock AnalysisChartEarningsHeadlinesSEC FilingsShort InterestBuy This Stock BIXT Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 Time Period Bioxytran Unveils Revolutionary Precision Diagnostics on Tissue OxygenationAugust 15, 2025 | globenewswire.comBioxytran’s Breakthrough Broad-Spectrum Antiviral Technology Poised to Revolutionize Respiratory Infection TreatmentAugust 8, 2025 | finance.yahoo.comBioxytran's Breakthrough Broad-Spectrum Antiviral Technology Poised to Revolutionize Respiratory Infection TreatmentAugust 7, 2025 | globenewswire.comBioxytran Secures a Source of GMP Quality Camel HemoglobinJune 18, 2025 | globenewswire.comBioxytran’s Groundbreaking Stroke & Alzheimer’s Tech Gains Validation That Measures Oxygenation Uptake During StrokesJune 3, 2025 | finance.yahoo.comBioxytran's Groundbreaking Stroke & Alzheimer's Tech Gains Validation That Measures Oxygenation Uptake During StrokesJune 3, 2025 | globenewswire.comBioxytran’s Antiviral Breakthrough Featured in University of Georgia’s $100M HPAI Poultry Innovation Grand Challenge SubmissionMay 21, 2025 | finance.yahoo.comBioxytran's Antiviral Breakthrough Featured in University of Georgia's $100M HPAI Poultry Innovation Grand Challenge SubmissionMay 21, 2025 | globenewswire.comBIOXYTRAN, INC.: Bioxytran Completes Dose Optimization of Antiviral, ProLectin-MMay 12, 2025 | finanznachrichten.deBioxytran Completes Dose Optimization of Antiviral, ProLectin-MMay 12, 2025 | globenewswire.comBioxytran Marks 50 years of Mitochondrial Research with BXT-25 AdvancementsApril 11, 2025 | globenewswire.comBioxytran Marks 50 years of Mitochondrial Research with BXT-25 AdvancementsApril 10, 2025 | theglobeandmail.comBioxytran Signs NDA with the University of Georgia to Evaluate Galectin Antagonists for Bird Flu Treatment in ChickensMarch 19, 2025 | globenewswire.comBioxytran Develops New Treatment To Combat Bird Flu In Chickens, Potentially Saving BillionsMarch 14, 2025 | nasdaq.comBioxytran Develops a Groundbreaking Treatment to Combat Bird Flu in Egg Laying Chickens Potentially Saving BillionsMarch 12, 2025 | globenewswire.comBioxytran Secures $1.6 million SPA to Extinguish Note & Fund Clinical DevelopmentJanuary 22, 2025 | markets.businessinsider.comBioxytran restates financials, shares not to be relied uponJanuary 13, 2025 | investing.comBioxytran’s Cancer Preprint Reveals Potential to Enhance Most Immunotherapy DrugsJanuary 10, 2025 | markets.businessinsider.comBioxytran's Cancer Preprint Reveals Potential to Enhance Most Immunotherapy DrugsJanuary 10, 2025 | globenewswire.comBioxytran Announces Government Interest After Initial BARDA Techwatch Light MeetingJanuary 7, 2025 | markets.businessinsider.comNRx Pharmaceuticals added to Emerging Growth Conference 76 on October 31 and Update to ScheduleOctober 31, 2024 | markets.businessinsider.comBioxytran Expands Portfolio with NDPD Pharma AcquisitionOctober 29, 2024 | msn.comDIAM:CA Star Diamond CorporationSeptember 21, 2024 | seekingalpha.comBioxytran, Inc. (BIXT)August 28, 2024 | finance.yahoo.comBioxytran Launches Joint Venture with the Heme Foundation for Development of Universal Oxygen CarrierJuly 18, 2024 | globenewswire.comBioxytran's Advisor Releases Book on Hyperbaric Oxygenation Related to Stroke & Alzheimer's PatientsJune 27, 2024 | globenewswire.comBIXT: Carbohydrate Drug Design in the Fight Against VirusesMarch 20, 2024 | msn.comBioxytran Announces Preprint of Shingles Case Study Showing Clearance Using a Topical Galectin-3 AntagonistMarch 6, 2024 | globenewswire.comBioxytran’s Oral Antiviral Drug to Enter Dose Optimization Clinical Trial for COVID-19February 21, 2024 | finance.yahoo.comBioxytran's Oral Antiviral Drug to Enter Dose Optimization Clinical Trial for COVID-19February 21, 2024 | globenewswire.comBioxytran Gets Broad Patent Coverage on 60+ VirusesOctober 24, 2023 | finance.yahoo.comBioxytran Announces Broad Spectrum Antiviral Activity Highlighted in ProLectin-MSeptember 14, 2023 | finance.yahoo.comBioxytran Received IND Application by the FDA for Clinical Trials with ProLectin-M to Treat COVID-19 patientsSeptember 6, 2023 | benzinga.comFDA grants clearance to Bioxytran’s IND for Covid-19 trial initiationAugust 25, 2023 | msn.comBioxytran Announces FDA Clearance of its IND Application for ProLectin-M in Clinical TrialsAugust 24, 2023 | finance.yahoo.comBioxytran Initiates a Registrational Trial of Oral ProLectin-M for Mild to Moderate COVID-19 PatientsAugust 8, 2023 | finance.yahoo.comBioxytran Names Leslie Ajayi as Interim CMO and Head of the Medical Advisory BoardJuly 31, 2023 | finance.yahoo.comBioxytran Peer-Reviewed Journal in "Vaccines" Contains Mechanism Capable of Targeting Future COVID-19 MutationsJune 27, 2023 | it.tmcnet.comBioxytran Peer-Reviewed Journal in “Vaccines” Contains Mechanism Capable of Targeting Future COVID-19 MutationsJune 27, 2023 | finance.yahoo.comBioxytran expands institutional investor base with $0.5M equity investmentJune 12, 2023 | msn.comBioxytran Expands Institutional Investor Base with an additional $500,000 Equity InvestmentJune 12, 2023 | finance.yahoo.comBioxytran Tests Acellular Oxygen Carrier BXT-25 in Pre-Clinical TrialsApril 19, 2023 | finance.yahoo.comBioxytran Announces Positive Phase 2 Trial Results were Featured in "Vaccines" a Peer-Reviewed JournalMarch 29, 2023 | tmcnet.comBioxytran Announces Positive Phase 2 Trial Results were Featured in “Vaccines” a Peer-Reviewed JournalMarch 29, 2023 | finance.yahoo.comBioxytran, Inc. (BIXT) Stock Historical Prices & Data - Yahoo FinanceMarch 6, 2023 | finance.yahoo.comProLectin-M Demonstrates Significant Activity Against Influenza and Respiratory Syncytial VirusFebruary 28, 2023 | finance.yahoo.comNature Reviews Drug Discovery Article Offers Independent Support for ProLectin-I in Fibrosis and ProLectin-M as an Antiviral DrugFebruary 22, 2023 | finance.yahoo.comBioxytran to Appear on ClearThink IR’s Virtual Live EventFebruary 14, 2023 | finance.yahoo.comBioxytran drug candidates ProLectin-M and ProLectin-I progressing as COVID-19 treatmentsFebruary 8, 2023 | proactiveinvestors.comBioxytran Receives Approval to Initiate Trials with ProLectin-IFebruary 6, 2023 | finance.yahoo.com Get Bioxytran News Delivered to You Automatically Sign up to receive the latest news and ratings for BIXT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BIXT Media Mentions By Week BIXT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BIXT News Sentiment▼-1.000.94▲Average Medical News Sentiment BIXT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BIXT Articles This Week▼10▲BIXT Articles Average Week Get the Latest News and Ratings for BIXT and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Bioxytran and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Cadrenal Therapeutics News Today Enlivex Therapeutics News Today FibroBiologics News Today Akari Therapeutics News Today Oncotelic Therapeutics News Today Natural Alternatives International News Today NanoViricides News Today Synergy CHC News Today Passage Bio News Today Allarity Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:BIXT) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersNew Biotech Backed by Proven Incubator Now Open to PublicA successful biotech incubator just opened its next chapter - and you're invited to their raise. This deal ...i2i Marketing Group, LLC | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThis Coin Could Explode, and it’s Hiding in Plain Sight!The #1 coin with skyrocket potential right now... Sometimes the biggest opportunities are hiding in plain s...Crypto 101 Media | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredDalio’s $319 Million Gold BetA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bioxytran, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bioxytran With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BIXT Stock Alerts